CASI stock forecast
Our latest prediction for CASI Pharmaceuticals, Inc.'s stock price was made on the May 20, 2020 when the stock price was at 2.46$.
In the short term (2weeks), CASI's stock price should outperform the market by 6.23%. During that period the price should oscillate between -10.72% and +25.22%.
In the medium term (3months), CASI's stock price should underperform the market by -1.74%. During that period the price should oscillate between -36.31% and +42.09%.Get email alerts
Create a solid portfolio with CASI
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.
At the moment the company generates 8M USD in revenues.
On its last earning announcement, the company reported a loss of -0.48$ per share.
The book value per share is 0.96$
Three months stock forecastMay 20, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|